{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-032700","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.200722+00:00","generated_at":"2026-05-31T08:51:24.811907+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Serina Therapeutics appoints Gregory S. Curhan as CFO, replaces departing interim CFO Andrea Park","bullets":["Gregory S. Curhan appointed CFO effective Aug 16, 2024; compensated at $650/hour plus 250k-share option vesting over 48 months.","Andrea Park, interim CFO and CAO, departs effective Aug 15, 2024.","Curhan is partner at FLG Partners and also CFO of Curevo Vaccines.","Option accelerates on change of control or $60M equity transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-032700","json":"https://secwatch.observer/filing/0001493152-24-032700.json","markdown":"https://secwatch.observer/filing/0001493152-24-032700.md","text":"https://secwatch.observer/filing/0001493152-24-032700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/0001493152-24-032700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:51:24.811907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5989ce3c44","claim":"Gregory S. Curhan was appointed as Chief Financial Officer at Serina Therapeutics, Inc..","evidence_excerpt":"On August 15, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Gregory S. Curhan as the Company’s Chief Financial Officer in a non-employee consultant role, effective August 16, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/0001493152-24-032700-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"da6a749964","claim":"Andrea Park departed as Interim Chief Financial Officer and Chief Accounting Officer at Serina Therapeutics, Inc..","evidence_excerpt":"On August 12, 2024, the Company informed Andrea Park, the Company’s Interim Chief Financial Officer and Chief Accounting Officer, that her employment with the Company will end effective August 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/0001493152-24-032700-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"informed that employment will end"},{"label":"Role","value":"Interim Chief Financial Officer and Chief Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}